117 related articles for article (PubMed ID: 19995707)
21. [Molecular pathology of epithelial ovarian neoplasias: from the phenotype-genotype correlation to new targets in diagnostics and therapy].
Staebler A; Diebold J
Pathologe; 2007 May; 28(3):180-6. PubMed ID: 17431628
[TBL] [Abstract][Full Text] [Related]
22. Origin and prognostic value of circulating KRAS mutations in lung cancer patients.
Gautschi O; Huegli B; Ziegler A; Gugger M; Heighway J; Ratschiller D; Mack PC; Gumerlock PH; Kung HJ; Stahel RA; Gandara DR; Betticher DC
Cancer Lett; 2007 Sep; 254(2):265-73. PubMed ID: 17449174
[TBL] [Abstract][Full Text] [Related]
23. REDD1 and p-AKT over-expression may predict poor prognosis in ovarian cancer.
Jia W; Chang B; Sun L; Zhu H; Pang L; Tao L; Zou H; Du J; Dong Y; Qi Y; Jiang J; Liang W; Li F; Zhao X
Int J Clin Exp Pathol; 2014; 7(9):5940-9. PubMed ID: 25337238
[TBL] [Abstract][Full Text] [Related]
24. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
[TBL] [Abstract][Full Text] [Related]
25. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
Neumann J; Zeindl-Eberhart E; Kirchner T; Jung A
Pathol Res Pract; 2009; 205(12):858-62. PubMed ID: 19679400
[TBL] [Abstract][Full Text] [Related]
26. Molecular pathology of epithelial ovarian cancer.
Christie M; Oehler MK
J Br Menopause Soc; 2006 Jun; 12(2):57-63. PubMed ID: 16776856
[TBL] [Abstract][Full Text] [Related]
27. K-ras alterations in Danish ovarian tumour patients. From the Danish "Malova" Ovarian Cancer study.
Høgdall EV; Høgdall CK; Blaakaer J; Christensen L; Bock JE; Vuust J; Glud E; Kjaer SK;
Gynecol Oncol; 2003 Apr; 89(1):31-6. PubMed ID: 12694651
[TBL] [Abstract][Full Text] [Related]
28. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis.
Kurman RJ; Visvanathan K; Roden R; Wu TC; Shih IeM
Am J Obstet Gynecol; 2008 Apr; 198(4):351-6. PubMed ID: 18395030
[TBL] [Abstract][Full Text] [Related]
29. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors.
Ichikawa Y; Nishida M; Suzuki H; Yoshida S; Tsunoda H; Kubo T; Uchida K; Miwa M
Cancer Res; 1994 Jan; 54(1):33-5. PubMed ID: 8261457
[TBL] [Abstract][Full Text] [Related]
30. High frequency of beta-catenin mutations in borderline endometrioid tumours of the ovary.
Oliva E; Sarrió D; Brachtel EF; Sánchez-Estévez C; Soslow RA; Moreno-Bueno G; Palacios J
J Pathol; 2006 Apr; 208(5):708-13. PubMed ID: 16429393
[TBL] [Abstract][Full Text] [Related]
31. Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer.
Gorringe KL; Choong DY; Williams LH; Ramakrishna M; Sridhar A; Qiu W; Bearfoot JL; Campbell IG
Neoplasia; 2008 Nov; 10(11):1253-8. PubMed ID: 18953434
[TBL] [Abstract][Full Text] [Related]
32. Exclusive KRAS mutation in microsatellite-unstable human colorectal carcinomas with sequence alterations in the DNA mismatch repair gene, MLH1.
Zhao Y; Miyashita K; Ando T; Kakeji Y; Yamanaka T; Taguchi K; Ushijima T; Oda S; Maehara Y
Gene; 2008 Nov; 423(2):188-93. PubMed ID: 18692554
[TBL] [Abstract][Full Text] [Related]
33. The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: a comparison between direct sequencing and real-time PCR.
Kobunai T; Watanabe T; Yamamoto Y; Eshima K
Biochem Biophys Res Commun; 2010 Apr; 395(1):158-62. PubMed ID: 20361930
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic events associated with endometrial and ovarian cancers are rare in endometriosis.
Vestergaard AL; Thorup K; Knudsen UB; Munk T; Rosbach H; Poulsen JB; Guldberg P; Martensen PM
Mol Hum Reprod; 2011 Dec; 17(12):758-61. PubMed ID: 21724579
[TBL] [Abstract][Full Text] [Related]
35. KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.
Heublein S; Grasse K; Hessel H; Burges A; Lenhard M; Engel J; Kirchner T; Jeschke U; Mayr D
BMC Cancer; 2013 Oct; 13():483. PubMed ID: 24139521
[TBL] [Abstract][Full Text] [Related]
36. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
37. KRAS mutation positive mucinous adenocarcinoma originating in mature ovarian teratoma: case report and review of literature.
Hershkovitz D; Vlodavsky E; Simon E; Ben-Izhak O
Pathol Int; 2013 Dec; 63(12):611-4. PubMed ID: 24422958
[TBL] [Abstract][Full Text] [Related]
38. Molecular Genetic Analysis of Ovarian Brenner Tumors and Associated Mucinous Epithelial Neoplasms: High Variant Concordance and Identification of Mutually Exclusive RAS Driver Mutations and MYC Amplification.
Tafe LJ; Muller KE; Ananda G; Mitchell T; Spotlow V; Patterson SE; Tsongalis GJ; Mockus SM
Am J Pathol; 2016 Mar; 186(3):671-7. PubMed ID: 26797085
[TBL] [Abstract][Full Text] [Related]
39. Biomolecular pathogenesis of borderline ovarian tumors: focusing target discovery through proteogenomics.
Vergara D; Tinelli A; Martignago R; Malvasi A; Chiuri VE; Leo G
Curr Cancer Drug Targets; 2010 Feb; 10(1):107-16. PubMed ID: 20088785
[TBL] [Abstract][Full Text] [Related]
40. A novel polymorphism in codon 25 of the KRAS gene associated with gallbladder carcinoma patients of the eastern part of India.
Pramanik V; Sarkar BN; Kar M; Das G; Malay BK; Sufia KK; Lakkakula BV; Vadlamudi RR
Genet Test Mol Biomarkers; 2011 Jun; 15(6):431-4. PubMed ID: 21375404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]